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Abstract
Background We determined whether there were disparities in
the likelihood of being diagnosed at a late stage for breast
cancer (BC) or colorectal cancer (CRC) in each of 40 states,
using the recently available US Cancer Statistics (USCS)
database.
Methods We extracted 981,457 BC cases and 558,568 CRC
cases diagnosed in 2004–2009. Separate multilevel regres-
sions were run for each state and each cancer type. Models
included person and area-level covariates and were identically
specified across states. The disparities foci were race or eth-
nicity (white, African-American, Hispanic, Asian, all other),
gender, and age (<40, 40–49, 50–64, 65–74, and 75+). Using
whites, males, and the oldest age group as reference groups,
we noted the statistically significant disparities coefficients (p
value ≤0.05) and translated the findings via a set of maps of
states in the USA.
Results National disparity estimates were not consistent with
disparities identified in the states. Some states had estimates
consistent with the national average, while others did not.
Patterns of disparities across states were different for each
covariate and mapped separately.
Conclusion National disparity estimates may mask what is true
at the more local, state level because national estimates can con-
found the effects of race with place. Cancer control efforts are
local and require locally relevant information to assess needs.
Findings from the period 2004–2009 establish valuable bench-
marks against which to assess changes following national health
reform implemented in 2010. The USCS database is a valuable
new resource that will facilitate future disparities research.
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Introduction
Cancer is the secondmost common cause of death in the USA,
exceeded only by heart disease, and accounts for nearly one of
every four deaths [6, 30]. In the USA, breast cancer (BC) is the
most common cancer in women and colorectal cancer (CRC)
is the third most common cancer in both men and women [6,
17]. There are disparities across population subgroups in the
incidence, mortality, and the likelihood of cancer being diag-
nosed at a late stage—which is associated with greatly in-
creased risk of mortality from cancer.
Incidence and death rates for CRC are about 35–40 %
higher in men than in women and are highest among
African-American men and women. African-American inci-
dence rates are about 20 % higher, and mortality rates are
about 45 % higher than those in whites. Hispanics, Asians,
and Native Americans have lower incidence and mortality
rates than whites or African-Americans. However, Native
Americans have disproportionately high mortality as com-
pared to the low incidence rates. Incidence and death rates
for CRC increase with age; about 90 % of new cases and
94 % of deaths occur in individuals 50 and older.
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Geographic differences in incidence and mortality rates for
CRC are considerable [5].
By comparison, BC incidence rates are highest among
non-Hispanic white women, followed by African-American
women, with lowest rates among Hispanic women. Asians,
Native Americans, and Hispanics have lower mortality rates
than non-Hispanic whites or African-Americans, with lowest
rates for Asian women. Despite higher incidence rates among
non-Hispanic whites, BC death rates are generally lower as
compared to African-American women. BC incidence and
death rates generally increase with age; 95 % of new cases
and 97 % of deaths occur in women 40 and older. Similar to
CRC, geographic differences in incidence and mortality rates
for BC are considerable [4].
To understand why higher incidence is not always accom-
panied by higher mortality, it is important to examine differ-
ences in the stage at which cancer is diagnosed. Both BC and
CRC screening rates are lower than optimal, resulting in later-
staged cancers at diagnosis [3, 6]. The high proportions of
late-stage diagnoses remain a public health concern, as it re-
sults in higher morbidity and mortality than would obtain with
optimal cancer screening utilization [2, 3, 14, 29, 31].
The 5-year survival rate for persons who received a diagnosis
of localized stage of CRC is 91 %, compared with 70 % for
regional stage and 11 % for distant stage. Similarly, the 5-year
survival rate for women who receive a diagnosis of localized
stage of BC is 98 %, compared with 84 % for regional stage
and 23 % for distant stage [16].
Henley et al. [14]) used comprehensive national cancer
data 2004–2006 and examined disparities in late-stage diag-
nosis of cancer by age and by race or ethnicity for people aged
50 or older. Roughly a third of new BC cases and roughly half
of new CRC cases were diagnosed at a late stage. The rates of
late-stage BC and CRC incidence were calculated for each age
group, gender, or race or ethnicity from pooled national data.
Asians and Pacific Islanders, American Indians and Alaska
Natives, and Hispanics had consistently lower late-stage rates
than whites or African-Americans, for both cancer types. The
rates of late-stage CRC incidence increased with age and were
highest among African-American men and women.
Late-stage BC incidence rates increased with age only through
age 79 and were highest among the age 60–79 group and
African-American women.
National Cancer Institute statistics online show that
late-stage diagnosis rates are higher among younger popula-
tions than among older populations for both BC and CRC
[24]. One recent study used the same national cancer data as
Henley et al. [14]) but over a longer time horizon (2004–2009)
and included cancer patients younger than age 50 to examine
predictors of late-stage disparities for BC and CRC. Using
multilevel logistic regression of national data pooled across
states, accounting for a variety of personal and place-specific
factors, they found that younger people (under age 65) had
much higher likelihood of late-stage diagnosis of BC or
CRC than older people; African-Americans had higher
rates of late-stage diagnosis than whites; and other races
or ethnicities (combined) had lower rates of late-stage
diagnosis than whites [21].
Several additional studies have used regression modeling
to examine various predictors of stage at diagnosis for BC and
CRC, using smaller data sets. Studies have examined low
SES, marital status, race or ethnicity, distance to closest pro-
vider, managed care penetration, area screening rates, resi-
dence in a racially segregated community, area poverty or
deprivation, lack of personal insurance, or percent uninsured
in the area, and type of personal health insurance as predictors
[7, 12, 15, 18, 19, 33]. Area poverty or deprivation, lack of
personal insurance, or percent uninsured in the area predicted
higher likelihood of late-stage BC diagnosis [7, 12, 15], and
patients privately insured or insured by Medicare plus supple-
mental plans had lower likelihood of late-stage cancer diag-
nosis than persons with other types of insurance [33]. In these
studies, race or ethnicity was classified into three groups:
white, African-American, and all others. More detailed break-
outs of races or ethnicities are needed for a better understand-
ing of disparities, which is one major contribution of the re-
search described here.
In addition to more detailed information regarding various
races and ethnicities, other disparities by age, by sex, and by
geographic area are important and need further study. While
Henley et al. [14]) used mapping of state-specific estimates
over total populations to demonstrate substantial geographic
variation in the rates of late-stage diagnosis, this work is de-
scriptive and does not help explain the geographic variation.
To describe geographic disparities by race or ethnicity, the
American Cancer Society published two reports (2012,
2013) which used mapping of state-specific estimates to dem-
onstrate that the death rates associated with CRC exhibit dif-
ferent geographic patterns across men and women, whites,
and African-Americans and that the death rates associated
with BC have varied geographic patterns across white and
African-American women. The reports did not provide infor-
mation on geographic patterns for other races or ethnicities,
but did demonstrate that disparities vary along both demo-
graphic and geographic dimensions.
The disentangling of geographic and demographic dispar-
ities is important for policies designed to reduce disparities in
health outcomes. There is increasing recognition that health
disparities vary widely among states in the USA, such that the
effects of geographic place may be difficult to disentangle
from racial, ethnic, social, economic, or cultural determinants
of health [9, 10, 20, 22, 23, 26, 32]. To see why this is a
problem, consider that the apparent national disparities mea-
sured for one racial group relative to whites may reflect dis-
advantages and cultural differences in the geographic places
where they are most heavily concentrated and thus reflect
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geographic rather than racial disparities. That is, most resi-
dents of those regions may be similarly disadvantaged, regard-
less of race. If this is true, examining more local areas (e.g.,
states vs national) for evidence of demographic disparities
would be comparing groups within a more similar context,
thus enhancing separation of the demographic from the geo-
graphic disparity. If demographic disparities then exist within
this local context, one could conclude it is the race, not the
place that is resulting in the disparity. National statistics on
health disparities derived from pooled data across states mask
the socio-ecological differences found within more local areas
(e.g., states) and may confound the geographic with the de-
mographic disparities.
The purpose of this paper is to provide evidence of
state-specific disparities in late-stage cancer diagnosis out-
comes, by race or ethnicity, sex, or age groups, using
individual-level data for the residents of each state. This evi-
dence regarding disparities should be valuable in cancer con-
trol planning activities led by the individual states. Achieving
this purpose requires population-based cancer registry data
pooled over time so that each state has a large enough number
of observations to ensure statistical reliability of the estimates.
Accordingly, we examined all newly diagnosed cancer
cases during 2004–2009 from the United States Cancer
Statistics (USCS) database, which is a population-based sur-
veillance system of cancer registries with data representing
96 % of the US population [27]. The database was developed
by a joint effort by the Centers for Disease Control and
Prevention (CDC) and the National Cancer Institute (NCI)
to provide a single, pooled-state database of reconciled, com-
parable cancer information geocoded at the local level to fa-
cilitate cancer control planning and evaluation [34]. This com-
prehensive database is now available inside National Centers
for Health Statistics (NCHS) and Census Research Data
Centers (RDCs) to qualified researchers [8].
The outcome of interest in this paper is the likelihood of
being diagnosed at a late stage, for either BC or CRC.
Nationally, the rates of late-stage diagnosis are higher for
CRC than for BC, but these rates do vary considerably across
the states [14]. Nationally, disparities in late-stage diagnoses
among minorities and whites are greater for BC than for CRC,
and women are more likely than men to be diagnosed at a late
stage of CRC [21], but it is not known whether these dispar-
ities vary among the states. Finally, disparities among younger
(than age 65) and older persons diagnosed with late-stage
cancer are large for both cancer types in national analysis
[21], but again, it is not known whether these disparities vary
among the states.
The main contributions of this paper are to examine
disparities in multiple dimensions, using predictive mul-
tivariate modeling rather than descriptive statistics.
Utilizing the very large USCS database enables the gen-
eration of state-specific findings that can be reliably
used to guide policy makers in their efforts to control
cancer and its burdens.
Methods
Understanding health disparities in late-stage diagnosis of
cancer requires modeling of the sources of these disparities
in a geospatial context using an approach that explicates the
social ecology of the health behaviors. Omitting the social
ecological variables increases the risk that racial, ethnic, sex,
or age coefficients will exhibit omitted variables bias. To as-
certain the independent effect of demographic status on the
late stage of cancer outcome, the social and health market
contexts must be held constant statistically by including these
other covariates in the model. In this paper, we use a compre-
hensive multilevel model specification similar to that used in
previous studies noted above and employ the same empirical
specification for all state-specific analyses to enhance compa-
rability across states.
More specifically, we used multilevel models to examine
associations with late-stage cancer diagnosis from predictors
at person and county levels. We merged county-level commu-
nity characteristics with person-level records from the USCS
registry data system (Table 1). Table 1 describes the variables
used in the state-specific modeling.
We specify a two-level random intercept logit model for the
late-stage diagnosis with patients nested in counties. We used
a multilevel modeling (MLM) framework for estimation be-
cause we wanted to fit the regression to individuals while
accounting for systematic, unexplained variation among
counties. Ignoring these county-level effects, when they are
important, is tantamount to having omitted variables in the
model, which can bias individual-level coefficient estimates,
such as the disparities estimates [11]. Because we seek unbi-
ased estimates of disparity coefficients for each state, we
adopted the two-level random intercept logistic regression es-
timated here. We estimated the regressions using SAS
GLIMMIX (SAS/STAT 2016). We estimated the logistic mul-
tilevel regression model of the binary cancer stage outcome
separately for each cancer type and each state. The models for
each cancer type used identical predictors, except CRC in-
cluded an indicator to differentiate males and females.
Study Population and Data
We obtained all BC and CRC cases diagnosed in 2004–2009
from the USCS database, available to researchers with ap-
proved projects inside the NCHS and Census RDCs. In this
study, we required information regarding the county of resi-
dence for each cancer patient so that we could include com-
munity contextual factors (uninsured, area screening, man-
aged care penetration, screening access/availability, and
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residential isolation by race or ethnicity) in our multilevel
modeling. While all but three states (Kansas, Maryland,
Minnesota) participate in the USCS registry data system, four
do not allow use of county of residence information (Illinois,
Michigan, Missouri, Ohio). We excluded from the analysis
these seven states and an additional state, Virginia, because
registry data were not available until 2007. We also excluded
Alaska and Hawaii, because their county designations are
much different than for mainland states (each island is a coun-
ty in Hawaii, and Alaska has boroughs rather than counties),
and data are missing for some county-level constructs.
After exclusions, this resulted in 40 states over the 2004–
2009 period.We restricted the sample to adults of all ages with
a first cancer diagnosis in 2004–2009. We excluded records
when BC or CRC were not the primary cancers, records with
unknown cancer stage or unstaged cancer, or when diagnosis
was by autopsy (<1 % of all cases). For BC, we excluded
males. These restrictions yielded a CRC study population of
558,568 individuals and a BC study population of 981,457
individuals. The state with the smallest number of cases was
Wyoming, with 1916 BC cases and 1163 CRC cases. The
state with the largest number of cases was California, with
135,895 BC cases and 71,458 CRC cases. Thus, the cancer
population sizes are sufficient in each state to ensure the sta-
tistical power needed to estimate the various demographic
disparities (Table 2).
We defined whites as the reference group in the race or
ethnicity assessments and included African-American,
Asian, Hispanic, and “all other” as minority group designa-
tions. We include age groups <40, 40–49, 50–64, 65–74, and
75. Thus, our sample includes all adults with BC and CRC, in
contrast to Henley et al. [14]) who truncated the population to
include only those individuals with the age of 50+. Population
data are from the USCS database [8], and county-level data
describing contextual characteristics of communities were ob-
tained from the RTI Spatial Impact Factor Database (https://
rtispatialdata.rti.org), which derives from numerous public
sources, such as the Centers for Medicare and Medicaid
Services and the US Census Bureau.
To the extent that states act independently to promote their
cancer control efforts, it is reasonable to model each state as a
separate system. This approach allows us to examine unique
effects of disparity covariates (e.g., race or ethnicity relative to
whites) on the outcome variables (i.e., likelihood of late-stage
diagnosis) and compare results across states. Independent
modeling of each state’s population in multilevel models,





Mean sdev Mean sdev
Outcome: whether cancer patient was diagnosed at a late stage
(regional or distant =1, else = 0)
0.308 0.461 0.543 0.498
Person-level predictors (source: USCS database: CDC 2015)
Female (reference male) Binary indicator that person is female 1.000 0.000 0.487 0.500
White (reference) Binary indicator that person is white 0.773 0.419 0.765 0.424
African-American Binary indicator that person is African-American 0.101 0.301 0.112 0.315
Hispanic Binary indicator that person is Hispanic 0.081 0.273 0.080 0.271
Asian/Pacific Islander Binary indicator that person is Asian/PI 0.033 0.177 0.031 0.172
Race all other Binary indicator that person is other 0.013 0.090 0.013 0.088
Age less than 40 Binary indicator that person is <40 0.051 0.220 0.027 0.163
Age 40–49 Binary indicator that person is 40–49 0.193 0.395 0.083 0.275
Age 50 to 64 Binary indicator that person is 50–64 0.379 0.485 0.314 0.464
Age 65 to 74 Binary indicator that person is 65–74 0.201 0.400 0.250 0.433
Age 75 plus (reference) Binary indicator that person is 75+ 0.176 0.381 0.325 0.468
County-level predictors for counties of residence (source: RTI 2015)
Isolation black Higher isolation index represents a lower chance
that minorities reside among whites, with a value
of 1 indicating a perfectly segregated society, 2005
0.257 0.214 0.259 0.217
Isolation Asian 0.072 0.086 0.068 0.085
Isolation Hispanic 0.216 0.203 0.209 0.205
Managed care % Population insured by managed care plans, 2001 15.9 14.7 15.3 14.7
Distance (miles) Based on 100 % FFS Medicare utilization of
mammography or endoscopy services, 2006
6.02 6.10 5.15 4.80
Screening rate (%) 23.60 3.18 11.05 1.43
Percent uninsured (%) % Population < age 65 with no health insurance, 2005 17.73 5.45 17.75 5.49
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which include person-level and community-level covariates,
results in robust disparity estimates that are adjusted to reflect
local market and socio-economic factors. Thus, we can deter-
mine whether minorities and whites have different outcomes,
when facing the same socio-ecological contexts.
Statistical Analysis
We estimated state-level disparities using multilevel logistic
models for individuals within each state, including as covari-
ates the same personal demographic (level 1) and community
(level 2) constructs in each state model, analyzed separately
for BC and CRC. Using the separate regression results for
each of the 40 states and two cancer types, we examined the
effects of race-ethnicity, gender (for CRC), and age on the
likelihood of late-stage diagnosis for BC and CRC.
Specifically, we wanted to answer the following research
questions:
& Are African-Americans, Asians, Hispanics, or Native
Americans more likely to be diagnosed at a late stage for
BC or CRC than whites, and if so, in which states?
& Are women more likely to be diagnosed at a late stage for
CRC than men, and if so, in which states?
& Are older persons more likely to be diagnosed at a late
stage for BC or CRC than younger persons, and if so, in
which states?
Translation of Findings
To display the results of model estimates for the state-specific
analysis would require 40 tables, one for each state included in
the database, to display separately estimated models of
late-stage diagnosis of BC and CRC. As an alternative, the








CRC cases Proportion CRC
cases diagnosed at
late stage
AL 20,788 0.35 13,660 0.52
AZ 20,517 0.31 10,520 0.55
AR 11,501 0.34 7556 0.59
CA 135,895 0.31 71,458 0.56
CO 18,275 0.30 8810 0.53
CT 17,949 0.26 9213 0.50
DE 3982 0.28 2195 0.55
FL 79,402 0.30 46,239 0.55
GA 35,706 0.32 19,681 0.55
ID 5160 0.32 2730 0.60
IN 25,045 0.30 16,100 0.52
IA 12,926 0.29 8412 0.58
KY 17,605 0.31 12,307 0.53
LA 17,390 0.34 11,754 0.57
ME 6820 0.27 3944 0.50
MA 33,513 0.25 17,264 0.50
MS 11,236 0.36 8002 0.55
MT 4163 0.29 2323 0.57
NE 7395 0.30 4689 0.58
NV 8366 0.32 4950 0.59
NH 6274 0.26 3354 0.49
NJ 40,729 0.31 22,519 0.55
NM 6824 0.31 3922 0.56
NY 89,085 0.29 49,076 0.53
NC 38,335 0.31 21,620 0.53
ND 2699 0.32 1885 0.52
OK 14,844 0.34 8941 0.55
OR 16,810 0.29 8200 0.60
PA 59,408 0.31 38,692 0.52
RI 5160 0.28 2838 0.51
SC 19,641 0.32 11,141 0.54
SD 3356 0.30 2161 0.51
TN 25,601 0.33 15,536 0.53
TX 79,097 0.34 44,674 0.56
UT 6935 0.34 3589 0.51
VT 3329 0.24 1618 0.50
WA 27,921 0.29 12,792 0.59
WV 7936 0.31 5951 0.51
WI 23,791 0.29 12,236 0.52
WY 1916 0.32 1163 0.54
Total 981,457 0.31 558,568 0.54
Fig. 1 State-specific proportions
of breast cancer cases diagnosed
at a late stage, 2004–2009
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statistically significant (p value ≤0.05) estimates of disparities
from these state-specific models were translated to the reader
via maps. We displayed the significant disparity coefficients
for all 40 states together, using a set of maps, one for each
racial, ethnic, or age-related disparity estimate. Using this
method, each state’s estimate was independent of estimates
in other states, reflecting the very different social, political,
economic, regulatory, and cultural environments across states.
Each disparity estimate was classified into three categories
to show if the disparity was significantly higher than the ref-
erence group (positive, associated with significantly higher
likelihood of late-stage cancer diagnosis), significantly lower
than the reference group (negative, associated with signifi-
cantly lower likelihood of late-stage cancer diagnosis), or
not statistically different (zero, no significant difference in
the likelihood of late-stage cancer diagnosis from the refer-
ence group). If we had used exponentiation to convert the
model estimates into odds ratios, the corresponding groupings
would be as follows: significantly greater than 1 (associated
with significantly higher odds of late-stage cancer diagnosis
than the reference group), not significantly different from 1
(not significantly different from reference group), or signifi-
cantly lower than 1 (associated with significantly lower odds
of late-stage cancer diagnosis than the reference group).
Results
Sample statistics are presented in Table 1, for the pooled na-
tional data. About 10–11 % of the cancer population are
African-American, and about 3 % are Asian, 8 % are
Hispanic, and ∼1 % are other races combined; the vast major-
ity are white, the reference group. Almost half (48.7 %) of
CRC cases are females. More than 62 % of the BC sample
are younger than 65 years old, whereas less than 43 % of the
CRC sample are people younger than 65. Thus in general, BC
Fig. 2 State-specific proportions
of colorectal cancer cases
diagnosed at a late stage, 2004–
2009
Fig. 3 State-specific disparities
in late-stage diagnosis of BC or
CRC, by African-Americans
versus whites
206 J. Racial and Ethnic Health Disparities (2017) 4:201–212
seems to be a “younger” disease at onset than CRC. In the
USA, screening protocols reflect these disease trajectories.
The BC screening protocols recommended screening to begin
at age 40, while CRC screening guidelines recommended
screening to begin at age 50.
Over all individuals (Table 1), the national average of
late-stage BC cases is 30.8 % and the national average of
late-stage CRC cases is 54.3 %. We use mapping to show
state-specific overall late-stage cancer diagnosis rates for BC
(Fig. 1) and CRC (Fig. 2). Vermont has the lowest percentage
of late-stage BC diagnoses (24.3 %), and Mississippi has the
highest (36.4 %), with the mean represented by the state of
New Jersey (30.8 %). For CRC, the state with the lowest
percentage of late-stage diagnoses is New Hampshire
(48.5 %), while the highest is Oregon (60 %) and the mean
is represented by Arizona (54.3 %).
The state-specific disparities effect estimates are presented
in Figs. 3, 4, 5, 6, 7, 8, 9, and 10. In these maps, we coded an
estimate “0” and used gray coloring in the maps whenever
there was no statistically significant disparity estimate in that
state’s regression (using a p value >0.05), for each demo-
graphic factor. Positive disparity estimates with a statistically
significant p value (p value ≤0.05) reflect higher likelihood
than the reference group of a late-stage diagnosis, while neg-
ative effect estimates with a statistically significant p value
reflect a “reverse” disparity (i.e., lower likelihood than the
reference group). Only statistically significant estimates are
colored with shades other than gray in the maps.
Fig. 4 State-specific disparities
in late-stage diagnosis of BC or
CRC, by Hispanics versus whites
Fig. 5 State-specific disparities in late-stage diagnosis of BC or CRC, by Asians versus whites
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For the research question concerning effect of race or eth-
nicity on late-stage BC and CRC, we found that
African-Americans (Fig. 3), Hispanics (Fig. 4), and Asians
(Fig. 5) are more likely to be diagnosed at a late stage for
BC or CRC or both than whites in many states. However,
there is a reverse disparity (e.g., designated group less likely
than reference group to be diagnosed at a late stage)—where
African-Americans are less likely than whites for late-stage
BC diagnosis—in Utah, Wyoming, and North Dakota. For
Asians, there is a reverse disparity for BC in California, but
an ordinary disparity (higher likelihood) for CRC. For
Hispanics, there is a reverse disparity for CRC in Louisiana,
but an ordinary disparity (higher likelihood) for BC.
For gender effects on late-stage diagnosis of CRC, Fig. 6
shows that eight states colored in red (CA, NV, NM, UT, PA,
NY, MA, ME) had significantly higher likelihood that women
would be diagnosed at a late stage for CRC, as compared to
men. (Note that MA is located above CT and RI.)
Figures 7, 8, 9, and 10 show age effects on late stage for BC
and CRC, in which each younger age group was compared to
the age 75 and older group. It is apparent that the age 65–74
group (Fig. 10) is less likely than the oldest group to be diag-
nosed late, in 18 states (colored white, light blue, and pink).
However, the two groups under age 65 are more likely than
the 75+ group to be diagnosed late, in the majority of states
(Figs. 7 and 8). The youngest group under age 40 (Fig. 7) is
more likely to be diagnosed late for BC or both cancer types
than those aged 75+, in every state. For the group aged 40–49
(Fig. 8), all but two states show significant disparities, but NJ
shows a reverse disparity for BC coupled with an ordinary
disparity for CRC (bright red) and Utah shows no significant
disparity. The group aged 50–64 (Fig. 9) shows a lot of vari-
ability across the USA. Five states have a significant disparity
in both cancer types relative to the oldest group (FL, WV, TX,
MT, NV), four show a significant CRC disparity (IN, AR, NE,
OK), and eleven others show a significant disparity for BC
Fig. 6 State-specific disparities
in late-stage diagnosis of CRC, by
women versus men
Fig. 7 State-specific disparities in late-stage diagnosis of BC or CRC, by group aged <40 versus 75+
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(WA, OR, ID, CO, AZ, NM, IA, TN, NC, SC, CA). The
remaining 20 states show negative (colors pink, light blue,
or white) or no disparities (gray) relative to the oldest group.
The age 65–74 group (Fig. 10) shows reverse disparities
across about half of the states (pink, light blue, white) with
the remaining states showing no disparity.
In addition, compared to people aged 75+, Fig. 9 also
shows a reverse disparity for CRC (light blue) for people aged
50–64 in states of Utah, New Hampshire, Massachusetts, and
Connecticut; a reverse disparity for BC (pink) in New Jersey;
and reverse disparities for both cancer types in Pennsylvania
and New York. Similarly, Fig. 10 shows an abundance of
states with reverse disparities for BC (pink) or CRC (light
blue) or both (white) for people aged 65–74 compared to those
aged 75+.
Discussion and Summary
Using the USCS database for new breast or colorectal cancers
diagnosed during 2004–2009, in 40 of the United States, we
identified similar raw proportions of late-stage diagnosis of
cancers to those reported by Henley et al. [14]). Our study
filled important gaps by estimating detailed demographic
Fig. 8 State-specific disparities in late-stage diagnosis of BC or CRC, by group aged 40–49 versus 75+
Fig. 9 State-specific disparities in late-stage diagnosis of BC or CRC, by group aged 50–64 versus 75+
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disparities for each state, identified as effect estimates from
multivariate and multilevel models which control for omitted
variables bias and yield reliable effect estimates. Findings
demonstrated considerable variability across states in the de-
mographic disparity dimensions we examined, which includ-
ed race or ethnicity, age, and gender. Thus, the national statis-
tics from previous studies have been parsed into their sub-
national components which may be helpful in forming state
policy to improve cancer control efforts.
For example , na t iona l s ta t i s t i cs sugges t tha t
African-Americans are more likely to be diagnosed at a late
stage for both BC and CRC as compared to whites (e.g., [14,
21]). This is apparently true in many states (Fig. 3, black
coloring), and the disparity is actually greater for BC than
for CRC (Fig. 3, black and dark blue coloring). The national
statistics do not pertain in all states, however. There are a few
states where a reverse disparity seems to exist for
African-American women (Fig. 3, pink coloring). There are
also a few states in New England with no apparent disparities
for African-Americans for either type of cancer (gray color-
ing). Finally, national stat is t ics suggest that the
African-American disparity is stronger for BC than for CRC,
which is borne out in mapping the individual state disparities
(Fig. 3) which reveals the local patterns across the states.
National statistics also suggest that breast cancer patients
under age 40 are generally at higher risk for more aggressive
tumors that are more difficult to treat and may pose worse
outcomes [28]. A particular subtype of BC, inflammatory
BC, is always diagnosed at a late stage and is an example of
extremely aggressive BC inflicting younger women, especial-
ly African-Americans [13]. More aggressive tumors increase
the odds of being diagnosed for BC at later stages, so our
finding that women in the youngest age group (under age
40, Fig. 7) are more likely to be diagnosed late for BC in every
state resonates with the clinical data regarding more aggres-
sive tumors among younger women. Our findings generally
demonstrate significant disparities in age, gender, and race or
ethnicity for late-stage BC and CRC. However, disparities are
not similar across the states for the two cancer types. Equal
findings across the two cancer types would result in maps with
only white, gray, and black colors. The states colored bright
red, or bright blue indicate situations where disparities for one
cancer type are positive (higher than the reference group),
while disparities for the other type are negative (lower than
the reference group). In these rare situations, disparity findings
are directly opposite across the cancer types. Four cases of
these opposites are found. First, in the Hispanic disparities
map (Fig. 4), this situation exists in Louisiana, where
Hispanics have significantly higher likelihood of late-stage
BC diagnosis, but significantly lower likelihood of late-stage
CRC diagnosis than whites. Second, in the Asian disparities
map (Fig. 5), this situation exists in California, where Asians
have significantly higher likelihood of late-stage CRC diag-
nosis, but significantly lower likelihood of late-stage BC di-
agnosis than whites. Third, in the aged 40–49 disparities map
(Fig. 8), this situation exists in New Jersey, where cancer
patients aged 40–49 have significantly higher likelihood of
late-stage CRC diagnosis, but significantly lower likelihood
of late-stage BC diagnosis than the group aged 75+. Fourth, in
the aged 50–64 disparities map (Fig. 9), this situation exists in
California, where cancer patients aged 50–64 have significant-
ly higher likelihood of late-stage BC diagnosis, but signifi-
cantly lower likelihood of late-stage CRC diagnosis than the
group aged 75+.
Fig. 10 State-specific disparities in late-stage diagnosis of BC or CRC, by group aged 65–74 versus 75+
210 J. Racial and Ethnic Health Disparities (2017) 4:201–212
National statistics suggest overall trends, but mask impor-
tant differences that may exist from state to state. When pop-
ulation health data are available to researchers, the variability
across the landscape can be reliably explored, using popula-
tion sizes sufficient to yield statistically significant findings at
sub-national scales. A limitation is that only 40 of the 50
United States provided the full dataset needed for this analy-
sis. Perhaps the findings from the states included will encour-
age more reluctant states to join the USCS database effort.
This study has established disparities benchmarks based on
the 2004–2009 period for the late-stage diagnosis of BC and
CRC. Further research inside the RDC labs can assess these
disparities in the more current time, beginning in 2010, when
landmark health policy legislation was enacted in the USA.
The Patient Protection and Affordable Care Act of 2010 [1]
mandated that all new private insurance plans cover all costs
of colonoscopy for CRC screening and all costs of mammog-
raphy for BC screening, among other preventive services.
Prior to the act, copayments for colonoscopies had included
a significant percentage of procedure costs as out of pocket
expenditures and were subject to annual deductibles, and this
pertained to elderly persons on Medicare as well as younger
persons [25]. Another change that was implemented with the
ACA in 2010 was the ban on insurers’ use of pre-existing
condition clauses to refuse to underwrite or charge unafford-
able high premiums to the sick.
After 2010, we expect that a surge of unmet, pent-up de-
mand among the sick for preventive services would result in
lower late-stage diagnosis rates in the future. Time will tell
whether our expectation is met, and the USCS database in
the RDC will be an excellent data source for testing hypothe-
ses such as these. The value of this database for disparities
research in cancer control has barely been tapped and will
generate a lot of valuable research in the future.
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